Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Stock Analysis & Ratings

IONS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$25.04 - $44.42
Previous Close$39.25
Average Volume (3M)1.07M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-183.5
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $25.04 and its highest was $44.42 in the past 12 months.
    What is Ionis Pharmaceuticals’s market cap?
    Currently, no data Available
    What is Ionis Pharmaceuticals’s price target?
    The average price target for Ionis Pharmaceuticals is $52.20. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $92.00 ,the lowest forecast is $26.00. The average price target represents 32.99% Increase from the current price of $39.25.
      What do analysts say about Ionis Pharmaceuticals?
      Ionis Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
        When is Ionis Pharmaceuticals’s upcoming earnings report date?
        Ionis Pharmaceuticals’s upcoming earnings report date is Aug 03, 2022 which is in 39 days.
          How were Ionis Pharmaceuticals’s earnings last quarter?
          Ionis Pharmaceuticals released its earnings results on May 04, 2022. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.687 by $0.227.
            Is Ionis Pharmaceuticals overvalued?
            According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Ionis Pharmaceuticals pay dividends?
              Ionis Pharmaceuticals does not currently pay dividends.
              What is Ionis Pharmaceuticals’s EPS estimate?
              Ionis Pharmaceuticals’s EPS estimate is -$0.62.
                How many shares outstanding does Ionis Pharmaceuticals have?
                Ionis Pharmaceuticals has 141,797,850 shares outstanding.
                  What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
                  Ionis Pharmaceuticals reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.687. Following the earnings report the stock price went up 2.805%.
                    Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
                    Among the largest hedge funds holding Ionis Pharmaceuticals’s share is ARK Investment Management LLC. It holds Ionis Pharmaceuticals’s shares valued at 229M.


                      Ionis Pharmaceuticals Stock Analysis

                      Smart Score
                      Price Target
                      ▲(32.99% Upside)
                      Moderate Buy
                      The Ionis Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Ionis Pharmaceuticals

                      Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

                      Similar Stocks
                      Price & Change
                      Alnylam Pharma
                      Roche Holding
                      Johnson & Johnson

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis